Prothena Alzheimer's Med Hits Safety Goal in Phase 1

 

• Results from a single ascending dose (SAD) study in healthy volunteers demonstrated dose-proportional PRX005 concentrations in plasma with robust central nervous system (CNS) penetration of this potentially best-in-class investigational anti-MTBR-tau antibody
• Single doses of PRX005 across three dose cohorts were generally safe and well tolerated, meeting the primary objective of the study
• The Phase 1 multiple ascending dose (MAD) portion of the study is ongoing in healthy volunteers and patients with Alzheimer’s disease; topline results are expected by year end 2023

https://www.businesswire.com/news/home/20230131005981/en/Prothena-Reports-Topline-Phase-1-Single-Ascending-Dose-Study-Results-of-PRX005-a-Novel-Anti-MTBR-Tau-Antibody-for-the-Potential-Treatment-of-Alzheimer%E2%80%99s-Disease